ecrin-mdr-crcClinical2012Metastatic clorectal cancerMetastatic Clorectal CancerInterventionalhttps://newmdr.ecrin.org/Study/2624268Japan9ECRIN MDRActive, not recruitingfalseRandomized Phase III Study of mFOLFOX7 or CAPOX plus Bevacizumab versus 5-Fluorouracil/Leucovorin or Capecitabine plus Bevacizumab as First-line Treatment in Elderly Patients with Metastatic Colorectal Cancer (JCOG1018, RESPECT)Interventions: A: Fluoropyrimidine (5-FU/LVor capecitabine) + bevacizumab B: Fluoropyrimidine (5-FU/LV or capecitabine) + oxaliplatin + bevacizumab Primary outcome(s): Progression-free survival Study Design: Parallel Randomized2012-09-152624268JPRN-UMIN000008866